From Relapsed Hodgkin Lymphoma to Treatment Clarity: A Remote U.S. Second Opinion for a Complex Lymphoma Case
- SecondOpinion Support
- 6 hours ago
- 13 min read
Table of Contents |
Patient Overview
Patient: Ms. Y. (Alias), Israel, 70 years old.
Primary concern: Relapsed/refractory classic Hodgkin lymphoma arising from CLL/SLL through Richter transformation, with disease progression after multiple prior treatments.
Symptoms over the disease course: Significant weight loss, reduced stamina, poor appetite, sleep disturbance, and recurrent infections. She also developed immune-related myopathy after nivolumab.
Major treatment history: Diagnosed with CLL/SLL in 2013 and treated with rituximab plus CVP. In 2024, she developed classic Hodgkin lymphoma and received nivolumab-AVD, brentuximab-bendamustine, radiation therapy, and autologous stem cell transplantation. After complete metabolic remission in May 2025, the disease later recurred and progressed. She is now receiving pembrolizumab with prednisone support.
Important history points: Long-standing CLL/SLL, prior transplant, pancytopenia, abnormal thyroid function, recurrent infections, significant weight loss, and reduced treatment tolerance.
Consultation goal: To clarify whether pembrolizumab alone is enough, whether prednisone should be reduced, when PET-CT and biopsy should be done, what combination treatments may be considered, and whether donor stem cell transplantation remains possible.
Understanding the Diagnosis
The patient’s medical journey began in 2013, when she was diagnosed with CLL/SLL with lymph node involvement. CLL/SLL is usually considered an indolent, or slower-growing, lymphoid cancer. She received rituximab plus CVP chemotherapy between June and December 2013.
In 2022, enlarged lymph nodes were again seen in the left axillary area, meaning the lymph nodes under the left arm. A biopsy showed CLL/SLL with scattered Reed-Sternberg-like cells. Reed-Sternberg cells are abnormal cells commonly associated with Hodgkin lymphoma. However, at that time, the findings did not fully meet the diagnostic criteria for Hodgkin lymphoma.
By April 2024, the diagnosis had evolved. The patient was diagnosed with classic Hodgkin lymphoma developing from CLL/SLL. This was considered a form of Richter transformation. Richter transformation means that a previously slower lymphoma changes into a more aggressive lymphoma type.
The patient received nivolumab plus AVD chemotherapy. Nivolumab is an immune checkpoint inhibitor, a medicine designed to help the immune system recognize and attack cancer cells. AVD is a chemotherapy combination commonly used in Hodgkin lymphoma. However, nivolumab was stopped because of worsening myopathy, meaning muscle inflammation or muscle weakness thought to be immune-related.
She later received brentuximab vedotin with bendamustine, followed by radiation therapy to the left axilla. In March 2025, she underwent autologous stem cell transplantation, meaning her own stem cells were collected and later reinfused after intensive treatment. A PET-CT scan in May 2025 showed complete metabolic remission, meaning no active cancer uptake was seen on that scan.
Unfortunately, by September 2025, PET-CT imaging showed new abnormal uptake in abdominal lymph nodes. By January 2026, imaging showed disease progression with worsening abdominal lymphadenopathy and concerning bone findings.
Why a Second Opinion Was Needed
This case raised several difficult questions.
The patient had already gone through many major treatment steps. She had received chemotherapy, immune checkpoint therapy, brentuximab-based treatment, radiation, and autologous stem cell transplantation. Despite these treatments, the disease returned and appeared to progress.
The patient was also physically fragile. She had lost significant weight, had reduced stamina, and had experienced multiple infections, including urinary tract infection, pneumonia, and Helicobacter pylori gastritis. Her blood tests also showed pancytopenia, meaning low levels of multiple blood cell types, including red blood cells, white blood cells, and platelets.
Another concern was the use of prednisone. Prednisone is a corticosteroid, often used to reduce inflammation or prevent immune-related complications. In this patient’s case, prednisone was being used partly because of prior immune-related myopathy. However, the family wanted to understand whether prednisone could reduce the effectiveness of pembrolizumab, also known as Keytruda, which is another immune checkpoint inhibitor.
The patient also wanted to avoid surgery and preferred a conservative plan first, especially because of weakness and weight loss. At the same time, the family wanted to understand whether a donor stem cell transplant might still be possible in a 70-year-old patient.
These questions made the second opinion valuable. The purpose was not to criticize the local medical team. It was to help the patient and family understand the treatment options, risks, and timing more clearly.
The Remote Second Opinion Process
Through Medebound HEALTH, the case was reviewed remotely by Ann S. LaCasce, MD, MMSc, a U.S. hematology and oncology specialist with expertise in lymphoma, chronic lymphocytic leukemia, CAR T-cell therapy, and stem cell transplantation.
The specialist reviewed the patient’s available medical records, including the lymphoma history, pathology information, prior treatment timeline, PET-CT findings, blood test results, treatment tolerance issues, and current plan for pembrolizumab.
The consultation focused on several practical questions:
Whether pembrolizumab alone was likely to control the disease long term
Whether prednisone should be reduced because of possible interference with immunotherapy
Whether abdominal lymph node biopsy and bone marrow biopsy were needed
Whether CLL/SLL was still active in the bone marrow
Whether chemotherapy or other medicines should be added if pembrolizumab was not enough
Whether donor stem cell transplantation could still be considered
How to balance disease control with the patient’s current weakness, weight loss, and infection history
This type of remote review can help families organize complex information before making high-stakes treatment decisions with their local doctors.
Key Clinical Questions Reviewed
1. Should prednisone be continued during pembrolizumab treatment?
One of the key questions was whether prednisone could reduce the effect of pembrolizumab. Pembrolizumab is an immune checkpoint inhibitor. In plain terms, it works by helping the immune system stay active against cancer cells.
The U.S. specialist advised trying to limit steroid exposure as much as possible because steroids can potentially reduce the effectiveness of immune checkpoint therapy. However, the report also recognized why the local doctors were using prednisone: the patient previously experienced immune-related myopathy from nivolumab, and the clinical team was trying to prevent recurrence.
The recommendation was not to stop prednisone suddenly. Instead, steroid reduction should be gradual and based on the patient’s physical tolerance.
2. Could another medicine support appetite, sleep, and mood?
Because the patient had weight loss, poor appetite, and sleep disturbance, the specialist suggested considering low-dose mirtazapine. Mirtazapine is an antidepressant that is sometimes also used to support appetite and sleep.
In this case, the suggestion was clinically practical because it could potentially help several issues at once: appetite, mood, and sleep. It may also reduce reliance on prednisone for appetite support, depending on the treating physician’s judgment.
3. Was biopsy still necessary?
Yes. The specialist emphasized that biopsy would be important if disease remained active after several cycles of pembrolizumab.
A CT-guided core needle biopsy was suggested for an abdominal lymph node if feasible. This is a minimally invasive biopsy method where a needle is guided by CT imaging to collect tissue. The goal would be to confirm whether the abdominal disease represented Hodgkin lymphoma progression or another lymphoma-related process.
A bone marrow biopsy was also recommended because of cytopenias, meaning low blood counts. In plain terms, the low blood counts could be caused by lymphoma involvement in the marrow, previous transplant-related marrow damage, active CLL/SLL, or a combination of factors.
4. Was donor stem cell transplantation possible?
The specialist noted that allogeneic stem cell transplantation, meaning donor stem cell transplantation, was the only potentially curative option for long-term control. However, it is an aggressive treatment with significant risks.
The patient’s age alone was not considered an automatic reason to rule it out. But the specialist emphasized that transplant should only be considered if the disease could first be brought into remission and if the patient’s physical condition improved enough to tolerate the procedure.
Educational Insights from the U.S. Specialist
The specialist’s review helped organize the patient’s situation into a clearer decision pathway.
First, pembrolizumab could be continued initially, but the response should be assessed after three to four cycles using PET-CT. PET-CT is a scan that shows both anatomy and metabolic activity. In plain terms, it helps doctors see whether cancer areas are still active.
Second, if the PET-CT showed persistent disease, biopsy would become important. The abdominal lymph nodes represented a newer disease site compared with the earlier left axillary involvement. Because of this site change, tissue confirmation could reduce the risk of treating the wrong disease pattern.
Third, pembrolizumab alone was considered unlikely to provide durable long-term control, especially because the patient had previously received nivolumab, another checkpoint inhibitor, together with chemotherapy. If response was limited, the specialist discussed adding treatment such as dose-reduced gemcitabine, vinorelbine, and pegylated liposomal doxorubicin, or a hypomethylating agent such as decitabine or azacitidine.
Gemcitabine, vinorelbine, and liposomal doxorubicin are chemotherapy medicines. In this patient’s case, the emphasis was on reduced dosing because her bone marrow reserve and overall tolerance were major concerns.
Hypomethylating agents are medicines that can affect how cancer cells grow and behave. They may be considered in certain blood cancers and complex lymphoma situations, depending on the treating team’s judgment.
Fourth, if biopsy showed ongoing CLL/SLL activity, the specialist suggested that a BTK inhibitor such as zanubrutinib could be considered. A BTK inhibitor is a targeted therapy used in certain B-cell blood cancers, including CLL/SLL.
Finally, donor stem cell transplantation was discussed as a possible future option, but not as an immediate next step.
The patient would first need disease control, improved weight, stronger physical condition, and a detailed risk discussion with the transplant team.
Treatment Direction After the Hodgkin lymphoma second opinion
After the Hodgkin lymphoma second opinion, the practical direction became more structured.
The patient could continue pembrolizumab while reducing prednisone carefully if tolerated. The next major checkpoint would be PET-CT after three to four cycles. This scan would help determine whether pembrolizumab was controlling the disease.
If the scan showed poor response or persistent disease, the next step would be tissue confirmation through biopsy. The abdominal lymph node biopsy would help clarify the current lymphoma type and disease behavior. The bone marrow biopsy would help determine whether the low blood counts were related to Hodgkin lymphoma involvement, CLL/SLL activity, prior transplant effects, or reduced marrow reserve.
Treatment adjustment would then depend on biopsy findings. If Hodgkin lymphoma remained active, pembrolizumab could potentially be combined with carefully selected additional therapy. If CLL/SLL was active, a targeted treatment such as zanubrutinib could be considered.
For long-term disease control, donor stem cell transplantation remained an important discussion. However, the patient’s preference for conservative treatment first was respected. The specialist’s review supported stabilizing the disease and improving physical condition before making a transplant decision.
Why This Case Was Medically Complex
This case was complex for several reasons.
First, the patient had two related but different disease processes: CLL/SLL and classic Hodgkin lymphoma arising through Richter transformation. This makes treatment decisions more difficult because doctors must determine which disease process is currently active.
Second, the lymphoma had changed location. Earlier disease was mainly in the left axillary region, while later disease involved abdominal lymph nodes and possible bone sites. When disease appears in a new location, biopsy can be important to confirm the exact diagnosis.
Third, the patient’s bone marrow function was a major concern. Bone marrow is where blood cells are made. Low blood counts can make chemotherapy riskier and can increase the chance of infection, bleeding, fatigue, and treatment delays.
Fourth, the patient had already experienced serious treatment-related complications, including immune-related myopathy, infections, mucositis after transplant, weight loss, and reduced stamina.
Fifth, the future possibility of donor stem cell transplantation required careful timing. The treatment could offer the possibility of long-term disease control, but it also carries significant risks, including graft-versus-host disease. Graft-versus-host disease means donor immune cells may attack the patient’s healthy tissues.
For these reasons, the second opinion did not simply answer one question. It created a step-by-step framework for decision-making.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
How Medebound HEALTH Supports Complex Oncology Second Opinions
Medebound HEALTH is a U.S.-based medical coordination service that helps international patients access independent remote second opinions from U.S.-licensed physicians and specialists.
For complex oncology cases, the process may include organizing medical records, translating and summarizing case history, identifying the appropriate specialist, coordinating a written review or video consultation, and helping the patient prepare questions for their treating doctors.
In this case, the second opinion helped clarify the role of PET-CT timing, biopsy planning, prednisone reduction, possible combination therapy, supportive care, and future transplant evaluation.
Medebound HEALTH does not replace the patient’s treating medical team. Instead, the service helps patients and families obtain additional expert information that they can discuss with their local physicians.
Important Points to Understand
This case shows why a second opinion can be helpful in relapsed or refractory lymphoma, especially when the patient has already received several lines of treatment.
A second opinion may help clarify whether more testing is needed before changing treatment. It may also help families understand why one treatment is being continued, when it should be reassessed, and what alternatives may be considered if the current approach is not enough.
For this patient, the most important insights were practical:
Repeat PET-CT after three to four cycles of pembrolizumab
Reduce prednisone as much as safely possible under medical supervision
Consider low-dose mirtazapine for appetite, sleep, and mood support
Use biopsy to confirm the active disease process before major treatment changes
Consider combination therapy if pembrolizumab alone is not effective
Keep donor stem cell transplantation as a possible future option, but only after remission and physical strengthening
Seeking a second opinion is not a rejection of the first medical team. It is a way for patients and families to make informed decisions when the situation is medically complicated.
How Does This Process Look?
Specialist selection
Each case is reviewed and directed to a U.S.-licensed physician whose background fits the clinical problem. For hepatobiliary cancer cases, this may include specialists with expertise in hepatocellular carcinoma, liver-directed therapy, transplant-related treatment planning, and advanced GI oncology.
Case file preparation
Before the review takes place, the medical records are organized into a structured format. This may include operative reports, pathology, liver imaging, treatment history, adverse-event history, lab trends, hepatitis status, and other records that affect treatment choice. The documentation can also be translated to support a clearer specialist review.
Structured written opinion
The main deliverable is a written physician-to-physician summary that captures the consulting specialist’s educational perspective. Depending on the case, this may address resection candidacy, local-regional treatment choice, systemic therapy sequence, transplant feasibility, the risk of side effects, and monitoring priorities after the next intervention.
Live clinical discussion
A scheduled video discussion can be arranged between the patient’s local physician and the U.S. consulting specialist. This creates an opportunity for direct professional exchange around the imaging, treatment response, and the reasoning behind the proposed approach.
Decision support for next steps
The review may also help the local team think through planning questions, such as local therapy first versus immediate drug change, the role of genetic testing, how to preserve renal and hepatic function for later treatment, and whether transplant review or clinical trials should move earlier in the plan.
Important points to understand
This service is intended for international patients and families who want more insight before they make major medical decisions, cross-border care planning, and treatment escalation.
Insurance coverage for this type of coordinated educational review varies. Patients and families should confirm directly with their insurance company whether any part of the service may qualify for reimbursement.
The specialist input obtained through this process is educational and consultative. It does not create a physician-patient relationship between the U.S. consulting physician and the patient. It is not the same as in-person care and is limited by the absence of direct examination. The patient’s local physician remains responsible for diagnosis, prescriptions, treatment implementation, monitoring, and all final medical decisions.
All patients must complete informed consent documentation that explains the consultative nature of the service, confirms that participation is voluntary, and acknowledges the scope and limits of a remote record-based review.
In complex liver cancer cases, a second opinion may be most useful before a major transition point. That may include progression after first-line systemic therapy, a decision between surgery and local-regional treatment, transplant eligibility review, a planned shift to a new systemic regimen, or the question of whether a clinical trial should begin now or later.
FAQ: Frequently Asked Questions
What makes this lymphoma case complex?
This case is complex because the patient has long-standing CLL/SLL that later transformed into classic Hodgkin lymphoma. She has already received several major treatments, including chemotherapy, immunotherapy, radiation therapy, brentuximab-based therapy, and autologous stem cell transplantation. The disease later recurred and progressed, making the next treatment decision more difficult.
Why was a second opinion important in this case?
A second opinion was important because the patient had relapsed disease after multiple treatments and also had reduced treatment tolerance. The family needed clarity on whether pembrolizumab alone was enough, whether prednisone could affect immunotherapy, and whether biopsy or donor stem cell transplantation should be considered. The goal was to help the patient discuss a clearer plan with her local doctors.
Why are abdominal lymph node biopsy and bone marrow biopsy important?
The abdominal lymph node biopsy can help confirm whether the new disease site is still Hodgkin lymphoma or another lymphoma-related process. The bone marrow biopsy is important because the patient has low blood counts. It can help determine whether the low counts are due to lymphoma involvement, remaining CLL/SLL, prior transplant injury, or reduced marrow reserve.
How did Medebound HEALTH support this lymphoma second opinion case?
Medebound HEALTH helped organize the patient’s complex medical history, prior treatments, imaging results, biopsy information, and current clinical questions for review by a U.S. lymphoma specialist. In a case involving relapsed Hodgkin lymphoma, CLL/SLL, prior transplant, immunotherapy, and low blood counts, careful preparation of records was important so the specialist could focus on the most urgent treatment decisions.
Can Medebound HEALTH help with complex lymphoma cases?
Yes. Medebound HEALTH supports patients seeking second opinions for complex oncology and hematology cases, including lymphoma, leukemia-related conditions, relapse after transplant, immunotherapy questions, and treatment sequencing. The goal is to help patients and families better understand available options before discussing next steps with their local doctors.
What medical records are usually needed for a lymphoma second opinion?
Patients are usually asked to provide pathology reports, biopsy results, PET-CT or CT reports, blood test results, prior treatment summaries, medication history, transplant records if applicable, and current treatment plans. For lymphoma cases, pathology and imaging records are especially important because they help the specialist understand the disease type, disease sites, and treatment response.
Can Medebound HEALTH help patients prepare questions for the specialist?
Yes. Medebound HEALTH can help patients and families organize their concerns into clear medical questions. In this case, the main questions included whether pembrolizumab alone was enough, whether prednisone should be reduced, whether biopsy was needed, and whether donor stem cell transplantation remained possible.
Why is a U.S. second opinion useful when the patient already has local doctors?
A second opinion can provide an additional specialist perspective, especially when the case is medically complex or treatment options are difficult to compare. It does not mean the local doctors are wrong. It simply gives the patient and family more information to discuss with their treating team.
Disclaimer
We strive to maintain the accuracy of and regularly update the clinical context information described in this article. However, clinical outcomes may vary between individual patients. The information provided in this article is for general educational purposes only and is not intended as medical advice, diagnostic guidance, or treatment recommendations. It should never replace the careful clinical evaluation and personalized care provided by the patient’s attending physician.
The collaborative consultation service is independently coordinated and operated by Medebound HEALTH. All consultative guidance is provided by independent U.S.-licensed physicians in their individual professional capacity, and this service is not endorsed, provided, partnered with, or officially affiliated with any hospital or cancer center as an institution. This service does not replace clinical care or establish a physician-patient relationship between the U.S. specialist and the patient.
